Skip to main content
Premium Trial:

Request an Annual Quote

MDS Sciex Could Benefit from Parent s Restructuring

NEW YORK, Sept. 2 (GenomeWeb News) - MDS Sciex could benefit from its parent company's plans to restructure and focus resources and management on life sciences markets.

 

MDS said yesterday it will restructure its business in order to refocus resources on markets served by its MDS Pharma Services, MDS Nordion, and MDS Sciex units.

 

MDS further plans to reduce its overhead costs and "better align resources and infrastructure costs," according to the company. As part of its restructuring, the company will reduce its workforce by approximately 500 of its 9,000 employees, resulting in savings of $40 million-$45 million in 2006.

 

"A review of company assets which are not part of MDS's core focus is underway and focused on maximization of shareholder value," said MDS President and CEO Stephen DeFalco in a statement.

 

It was not immediately clear how the restructuring will specifically affect MDS Sciex, which makes mass spectrometers for drug discovery and life sciences. MDS Sciex has joint ventures with both Applied Biosystems and PerkinElmer.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.